Table 1.

Demographic and clinical data of four patients with statin-induced lung injury diagnosed at our institute

Variable	Case 1	Case 2	Case 3	Case 4
Age, years	41	61	85	83
Statin/daily dose, mg	Rosuvastatin/10	Rosuvastatin/10	Atorvastatin/5	Rosuvastatin/5
Duration of treatment, months	0.33	12	1.75	2
Clinical symptoms	Dyspnoea, fever, cough	Dyspnoea, fever	Dyspnoea, fever, cough	Dyspnoea, fever
HRCT findings	G	G, C, P	G, C, I, P	G, C
Bronchoalveolar lavage fluid
Celluar profile, % (M/L/N/E)	94.5/2.5/3/0	74/4/22/0	58.5/33/2.5/6	94.5/4.5/1/0
Foamy macrophages	+	+	+	+
Sudan black smear	+	+	+	+
Pulmonary function testing
Spirometry	Not done	Restrictive	Normal	Restrictive
DLCO, % of predicted	Not done	44	44	39
Laboratory findings*
ALT/AST	33/63	Not done	24/36	33/23
CK	240	Not done	79	10
CRP	69.2	4.39	4.99	25.5
Treatment
Discontinuation of statin	+	+	+	+
Steroid/daily dose, mg	Prednisolone/45	Prednisolone/30	Methylprednisolone/24	Prednisolone/30
Outcome	Resolution	Resolution	Resolution	Resolution

*ALT (reference, 0–40 U/l), AST (reference, 5–45 U/l), CK (reference, 27–168 U/l), CRP (reference, 0–0.5 mg/l).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, consolidation; CK, creatinine kinase; CRP, C-reactive protein; DL_CO, carbon monoxide diffusing capacity; E, eosinophil; G, ground-glass opacities; HRCT, high-resolution CT; I, interstitial opacities; L, lymphocyte; M, macrophage; N, neutrophil; P, pleural changes.